Fig. 4.

Knockdown of FOXO3a reverses lovastatin-induced C2C12 myotubes atrophy. A C2C12 myotubes were administered with three different FOXO3a siRNA (100 nM) for 48 h, proteins were extracted and immunoblotting was used to test the knockdown efficiency. B C2C12 myotubes were administered with FOXO3a siRNA for 48 h and incubated with lovastatin for another 24 h, MyHC was stained, and the inverted microscope was used to capture the pictures; C2C12 myotubes were calculated and analyzed with ImageJ. C C2C12 myotubes were administered with 10 µmol/L lovastatin (LV) + 50 µmol/L daidzein (DA) for 24 h, nuclear and cytoplasmic proteins were extracted. FOXO3a in total cell, nucleus and cytosol were tested by immunoblotting. The image J was used to quantify the protein. D C2C12 cells were administered with lovastatin (LV) + daidzein (DA) for 24 h, FOXO3a and DAPI were stained, and the confocal microscopy were used to capture the images. The mean ± SEM was used to represent the data. *p < 0.05; **p < 0.01; ***p < 0.001, (n = 3)